T2DM Clinical Trial
Official title:
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional). Eight healthy adult subjects or T2DM patients in each dose group (except for 0.5 mg dose group, only 4 subjects will be enrolled) are randomly assigned to subcutaneously injection of SHR-3167 or placebo according to 3:1 ratio.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04544319 -
Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg
|
Phase 1 | |
Recruiting |
NCT02037100 -
Sleep Disordered Breathing and Impaired Glucose Homeostasis in Obese Children
|
N/A | |
Recruiting |
NCT03563794 -
Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT01990469 -
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
|
Phase 3 | |
Active, not recruiting |
NCT05680129 -
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
|
Phase 3 | |
Active, not recruiting |
NCT04609631 -
Tai Chi for Comorbid Depression in T2DM Patients
|
N/A | |
Completed |
NCT05681273 -
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
|
Phase 1 | |
Active, not recruiting |
NCT05680155 -
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
|
Phase 3 | |
Recruiting |
NCT03564431 -
The Imaging Genetic Study of Type 2 Diabetes and Depression
|
||
Recruiting |
NCT05159882 -
Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM
|
Phase 3 |